SL Science Holding Limited Reports Full Year 2025 Financial Results

Globe Newswire — Thu, 18 Jun 2026 21:13:18 +0000

Taipei, TAIWAN, June 18, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited ("SL Science" or the "Company") (NASDAQ:SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced its financial results for the full year ended December 31, 2025.

Management Commentary

"2025 was a highly transformative and foundational year for SL Science as we aggressively advanced our core cell therapy pipeline and executed our long-term strategic shift toward next-generation immunotherapies. Throughout the past year, we strategically prioritized our resources on high-value clinical research and development, committing over $2.07 million to expand our proprietary cell platforms. This includes advancing our off-the-shelf Gamma Delta T (GDT) cell culture platforms, which is ready-to-use treatments to target significant unmet medical needs in blood, pancreatic, and brain cancers with scalable manufacturing and reduced cost. As part of this transition, we restructured our commercial model, shifting from direct retail sales to corporate distribution channels in Asia. While this structural pivot temporarily impacted our top-line revenue, it effectively freed up operational bandwidth to drive our therapeutic programs forward," said Mr. William Wang, Chairman and Chief Executive Officer of SL Science.

"We entered 2026 with tremendous momentum, culminating in the recently announced completion of our business combination and successful listing on the Nasdaq Global Market. This milestone, combined with our concurrent $7.8 million PIPE financing, provides the enhanced financial flexibility necessary to accelerate our growth strategy. It positions us to attract top-tier global scientific talent, facilitate potential future strategic acquisitions, and firmly support our near-term clinical operating requirements."

"Looking ahead, with the vision of establishing one of the leading allogeneic Gamma Delta T cell platforms in Asia with global commercialization potential, our focus is squarely on regulatory preparedness and preclinical execution. For our CD-19 Armed-T blood cancer program, we are actively addressing the FDA's initial feedback by conducting additional nonclinical validation and manufacturing scale-ups, aiming for a Pre-Investigational New Drug (IND) meeting and formal IND submission in the first quarter of 2027. Concurrently, our Unmodified GDT cell platform is progressing through technical transfers to an FDA-compliant contract development and manufacturing organization (CDMO). Unlike traditional autologous therapies, our GDT cell approach is designed to create scalable, ready-to-use treatments, aiming to address the high costs and production delays currently facing the oncology market. Our ultimate vision is to establish SL Science as a global clinical leader, optimizing patient outcomes through breakthrough cellular innovations."

SL Science's Full Year 2025 Financial Results

Through the Company's proprietary cell expansion, bispecific antibody engineering platforms, and legacy exosome commercial operations, SL Science is building a clinically driven oncology model designed to capture expansion within the multi-billion-dollar solid tumor therapeutics market. The following table presents selected summarized financial information derived from the Company's consolidated statements of operations for the years ended December 31, 2025 and 2024.

In thousands USD, except percentage data, differences due to rounding

For the years ended December 31,

2025

2024

Variance %

Net Revenue

2,197

3,364

Record High Revenue, Adjusted Income from Operations, and Net Income, Up 10.0%, 1.0%, and 1.5% Year-over-Year, Respectively^[1]

TOKYO, June 18, 2026 /PRNewswire/ -- LEIFRAS Co., Ltd. (NASDAQ:LFS) (the "Company" or "Leifras"), a sports and social business company dedicated to youth sports and community engagement and Japan's leading operator of children's sports schools and school club activity support businesses, today announced its unaudited financial results for the three months ended March 31, 2026.

First Quarter of Fiscal Year 2026 Financial Highlights

Revenue was JPY3.0 billion ($18.6 million), an increase of 10.0% from JPY2.7 billion for the same period last year.
Income from operations was JPY153.3 million ($1.0 million), compared to JPY166.1 million for the same period last year.
Net income was JPY124.3 million ($0.8 million), an increase of 1.5% from JPY122.5 million for the same period last year.
Adjusted income from operations was JPY167.8 million ($1.1 million), an increase of 1.0% from JPY166.1 million for the same period last year.
Basic and diluted earnings per share was JPY4.75 ($0.03), compared to JPY4.92 for the same period last year.

First Quarter of Fiscal Year 2026 Operational Highlights

Sports School Business

Number of members was 60,960, compared to 62,495 for the same period last year.
Revenue of the sports school business was JPY2.2 billion ($13.6 million), an increase of 5.6% from JPY2.0 billion for the same period last year.

Social Business

Number of club activities was 2,120, an increase of 7.6% from 1,971 for the same period last year.
Revenue of the social business was JPY791.4 million ($5.0 million), an increase of 24.1% from JPY637.7 million for the same period last year.

Management Commentary

Mr. Kiyotaka Ito, the Representative Director and Chief Executive Officer of Leifras, commented, "For the first quarter of fiscal year 2026, we achieved record highs in revenue, adjusted income from operations, and net income.^[1]

"For the sports school business, despite a temporary slight decrease in membership due to graduations, revenue increased by 5.6% due to higher monthly fees. Moving forward, we plan to focus on expanding our sports school membership base through both organic growth and strategic M&A.

"For the social business, the school club support business expanded under the tailwind of national policy, while the after-school daycare business grew in both scale and revenue, driving an increase in social business revenue by 24.1%. Although strategic investments and M&A-related expenses led to a slight decrease in operating income, we believe these investments are essential to supporting future expansion and unlocking long-term growth through business synergies.

"Fiscal year 2026 marks the first year of the Japanese government's 'reform implementation period' for school club activities, during which these activities are being transitioned to private-sector providers. We plan to fully leverage this powerful policy tailwind and continue to execute with focus. We remain committed to supporting the smiles and growth of children across borders and appreciate the continued support from our valued customers, partners, and shareholders."

Financial Condition

As of March 31, 2026, the Company had cash of JPY2.48 billion ($15.6 million), compared to JPY2.52 billion as of December 31, 2025.
Net cash used in operating activities was JPY140.9 million ($0.9 million), compared to JPY239.5 million for the same period last year.
Net cash used in investing activities was JPY22.5 million ($0.1 million), compared to JPY4.9 million for the same period last year.
Net cash provided by financing activities was JPY116.9 million ($0.7 million), compared to net cash used in financing activities of JPY181.6 million for the same period last year.

Financial Guidance

Following these financial results, there are no changes to Leifras' financial guidance last provided in its press release issued on April 8, 2026.

Revenue is expected to be between $82.9 million and $95.7 million for the fiscal year ending December 31, 2026, an increase of approximately 10.8% to 27.9% from $74.8 million for the fiscal year ended December 31, 2025.
Income from operations is expected to be between $4.5 million and $5.4 million for the fiscal year ending December 31, 2026, an increase of approximately 13.2% to 33.9% from $4.0 million for the fiscal year ended December 31, 2025.

The guidance is based on the assumption that no business acquisitions, restructuring activities, or legal settlements will take place during the period.

The guidance is translated at the FY2025 assumed exchange rate of ¥156.80 = $1.00 to eliminate the impact of foreign exchange volatility.

Exchange Rate Information

This announcement contains translations of certain Japanese Yen ("JPY") amounts into U.S. dollars ("USD," or "$") for the convenience of the reader. Translations of amounts from JPY into USD have been made at the exchange rate of JPY159.08 = $1.00, the exchange rate on March 31, 2026 set forth in the H.10 statistical release of the United States Federal Reserve Board.

About LEIFRAS Co., Ltd.

Headquartered in Tokyo, Leifras is a sports and social business company dedicated to youth sports and community engagement. The Company primarily provides services related to the organization and operations of sports schools and sports events for children. As of December 31, 2025, Leifras was recognized as one of Japan's largest operators of children's sports schools in terms of both membership and facilities by Tokyo Shoko Research. The Company's approach to sports education emphasizes the development of non-cognitive skills, following the teaching principle "acknowledge, praise, encourage, and motivate." The holistic approach that integrates physical and mental development sets Leifras apart in the industry. Building upon deep experience and know-how in sports education, Leifras also operates a robust social business sector, dispatching sports coaches to meet various community needs with the aim to promote physical health, social inclusion, and community well-being across different demographics.

For more information, please visit the Company's website: https://ir.leifras.co.jp/.

Non-GAAP Financial Measures

In the Company's report, it discusses key financial measures that are not calculated in accordance with the United States Generally Accepted Accounting Principles ("GAAP") to supplement its unaudited interim condensed consolidated financial statements presented on a GAAP basis. These non-GAAP financial measures are reconciled from their most directly comparable financial measures determined in accordance with GAAP as follows:

	For the Three Months Ended March 31,
	2025		2026		2026
	JPY		JPY		US$
INCOME FROM OPERATIONS		166,146,066		153,308,100		963,717
Plus: acquisition-related costs^(a)		-		14,505,152		91,181
Adjusted INCOME FROM OPERATIONS		166,146,066		167,813,252		1,054,898

(a)

Represents acquisition-related costs incurred in connection with the Company's acquisition activities, including transaction-related
costs, legal, financial and tax due diligence expenses, integration costs and other acquisition-related costs. These costs have been
added back for normalization purposes as they are not considered reflective of the Company's core operating performance.

The Company's primary non-GAAP financial measures and corresponding metrics reflect how it evaluates its current and prior year operating results. As new events or circumstances arise, these definitions could change. When the Company's definitions change, it provides the updated definitions. When items no longer impact its current or future presentation of non-GAAP operating results, it removes these items from its non-GAAP definitions.

Adjusted income from operations is a financial measure that is not calculated in accordance with GAAP (collectively referred to as the "non-GAAP financial measures"), and the use of the term adjusted income from operations may differ from similar measures reported by other companies and may not be comparable to other similarly titled measures. The Company believes the non-GAAP financial measure provides investors with useful information with respect to its historical operations. The Company presents the non-GAAP financial measure as a supplemental performance measure because the Company believes it facilitates a comparative assessment of the Company's operating performance relative to its performance based on its results under GAAP, while isolating the effects of some items that vary from period to period. Specifically, adjusted income from operations allows the Company to assess its performance without the impact of the specifically identified items that it believes do not directly reflect its core operations, including acquisition-related costs and other items that management does not consider reflective of its core operating performance. The non-GAAP financial measure also functions as a key performance indicator used to evaluate the Company's operating performance internally, and it is used in connection with the determination of incentive compensation for management, including executive officers.

As the Company's initial public offering was completed during the fiscal year ended December 31, 2025, and the related listing-related and transformational expenses were specific to its initial public offering and related transformation activities, the Company does not expect to incur such expenses in the fiscal year ending December 31, 2026 or future periods. Accordingly, beginning with the fiscal year ending December 31, 2026, the Company has revised its presentation of adjusted income from operations and removed listing-related and transformational expenses from the adjustments to adjusted income from operations for all historical periods presented.

Adjusted income from operations is not a measurement of the Company's financial performance under GAAP and should not be considered in isolation or as an alternative to income from operations or any other financial statement data presented as indicators of financial performance or liquidity, each as presented in accordance with GAAP. Consequently, the Company's non-GAAP financial measure should be considered together with its unaudited interim condensed consolidated financial statements, which are prepared in accordance with GAAP. The Company understands that although adjusted income from operations is frequently used by securities analysts, lenders and others in their evaluation of companies, it has limitations as an analytical tool, and you should not consider it in isolation, or as a substitute for analysis of the Company's results as reported under GAAP. Some of these limitations are: adjusted income from operations does not fully reflect the Company's cash expenditures, future requirements for capital expenditures or contractual commitments; adjusted income from operations does not reflect changes in, or cash requirements for, the Company's working capital needs; adjusted income from operations does not reflect the interest expense, or the cash requirements necessary to service interest or principal payments, on debt; and, although depreciation and amortization expenses are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and adjusted income from operations does not reflect any cash requirements for such replacements.

Because of these limitations, adjusted income from operations should not be considered as discretionary cash available to the Company to reinvest in the growth of the Company's business or as measure of cash that will be available to the Company to meet its obligations.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may," or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. These statements are subject to uncertainties and risks, including, but not limited to, the uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of the registration statement filed with the U.S. Securities and Exchange Commission (the "SEC"). Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the registration statement and other filings with the SEC. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov.

For more information, please contact:

LEIFRAS Co., Ltd.
Investor Relations Department
Email: [email protected]" target="_blank" rel="nofollow" rel="nofollow">[email protected]

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: [email protected]" target="_blank" rel="nofollow" rel="nofollow">[email protected]

Note: [1] Record high in US-GAAP figures since 2025.

LEIFRAS CO., LTD. AND SUBSIDIARIES
UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS

	December 31,		March 31,		March 31,
	2025		2026		2026
	JPY		JPY		US$
			(Unaudited)		(Unaudited)
ASSETS
CURRENT ASSETS
Cash		2,524,082,266		2,477,567,162		15,574,347
Accounts receivable, net		731,083,491		786,776,869		4,945,794
Inventories, net		21,578,477		13,735,828		86,345
Prepaid expenses		158,040,280		253,474,342		1,593,377
Other current assets		38,219,685		45,019,332		282,998
TOTAL CURRENT ASSETS		3,473,004,199		3,576,573,533		22,482,861

NON-CURRENT ASSETS
Property and equipment, net		96,456,471		99,659,727		626,475
Intangible assets, net		29,631,015		26,881,643		168,982
Operating lease right-of-use assets		482,694,859		477,316,039		3,000,478
Finance lease right-of-use assets		236,908,226		227,724,404		1,431,509
Long-term deposits		150,216,792		155,815,142		979,477
Long-term investment		5,736,500		25,056,000		157,506
Deferred tax assets, net		164,082,227		147,566,531		927,625
Goodwill		27,999,994		27,999,994		176,012
Other non-current assets		8,470,398		9,030,715		56,768
TOTAL NON-CURRENT ASSETS		1,202,196,482		1,197,050,195		7,524,832
TOTAL ASSETS		4,675,200,681		4,773,623,728		30,007,693

LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES

Full story available on Benzinga.com

CosmoFarm Delivers Record Q2 2026 Revenue of Over $15M, Representing $60+ Million Annualized Run-Rate; Adds Over 80 Pharmacies and Expands AI Automation and Facility Capacity

Globe Newswire — Thu, 18 Jun 2026 19:34:00 +0000

CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, CosmoFarm S.A. ("CosmoFarm"), delivered record revenue of over $15 million in the second quarter of 2026, representing an annualized run-rate of over $60 million.

CosmoFarm added more than 80 new pharmacies to its distribution network during the period, continuing the strong customer growth that has made it one of the leading pharmaceutical wholesalers in the greater Athens area.

To support this accelerating growth, Cosmos Health is increasing capital expenditure at CosmoFarm, investing in new robotic automation and artificial intelligence systems to enhance procurement, inventory management, and order fulfillment. The Company is also expanding the size of the CosmoFarm facility to accommodate higher volumes and continued network expansion.

These investments build on CosmoFarm's existing automated infrastructure, including ROWA and SSI SCHÄFER A-frame robotic systems, which have driven improvements in operational efficiency, unit economics, and profitability per customer.

Greg Siokas, CEO of Cosmos Health, stated: "CosmoFarm's record second quarter marks an important milestone, with revenue reaching an annualized run-rate of over $60 million. The addition of over 80 new pharmacies reflects the strength of our distribution platform and the trust of our growing customer base. By investing further in robotic automation, artificial intelligence, and expanded facility capacity, we are positioning CosmoFarm to sustain this momentum, improve margins, and continue scaling profitably."

About Cosmos Health Inc.

Cosmos Health Inc. (NASDAQ:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed ...

Full story available on Benzinga.com

These Analysts Increase Their Forecasts On Jabil Following Strong Q3 Earnings

Avi Kapoor — Thu, 18 Jun 2026 14:42:49 +0000

Jabil Inc. (NYSE:JBL) on Wednesday reported better-than-expected fiscal third-quarter 2026 results and raised its full-year guidance.

The company reported adjusted earnings of $3.16 per share, topping the analyst consensus estimate of $3.10. Revenue increased 12% year over year to $8.75 billion, exceeding analysts' expectations of $8.61 billion.

For the fiscal fourth quarter, Jabil expects revenue of $9.20 billion to $10.00 billion, above the analyst consensus estimate of $8.97 billion. The company forecasts adjusted earnings of $3.80 to $4.20 per share, compared with analysts' expectations of $3.72.

For fiscal 2026, Jabil raised its revenue outlook to $35.00 billion from its previous forecast of $34.00 billion, ahead of the analyst consensus estimate of $34.24 billion. The company also increased its adjusted earnings outlook to $12.70 per share from $12.25, topping the consensus estimate of ...

Full story available on Benzinga.com

Accenture Stock Crashes To 52-Week Low On Weak Outlook, Fed Jitters

Anusuya Lahiri — Thu, 18 Jun 2026 14:15:57 +0000

Accenture plc (NYSE:ACN) stock tumbled in Thursday’s trading after the consulting and technology services company reported fiscal third-quarter 2026 results that beat earnings estimates but missed revenue expectations and issued a weaker-than-expected revenue outlook.

The stock came under pressure as investors focused on the company’s softer guidance, a hawkish Federal Reserve stance that has pressured IT stocks, and its planned $4.18 billion cybersecurity acquisition spree.

Accenture Third-Quarter Earnings

Accenture reported third-quarter earnings of $3.80 per share, exceeding analysts’ estimates of $3.69. Revenue rose 6% year over year in U.S. dollars, or 3% in local currency, to $18.72 billion, slightly below the consensus estimate of $18.75 billion.

Segment Performance

Consulting revenue increased 4% in U.S. dollars, or 1% in local currency, to $9.33 billion. Managed Services revenue climbed 8% in U.S. dollars, or 5% in local currency, to $9.39 billion.

Among industry groups, Products revenue rose 6% to $5.67 billion. Health & Public Service revenue increased 2% to $3.85 billion. Financial Services revenue grew 6% to $3.49 ...

Full story available on Benzinga.com

Sony Group Corporation Files Annual Report on Form 20-F

PRNewswire — Thu, 18 Jun 2026 14:00:00 +0000

TOKYO, June 18, 2026 /PRNewswire/ -- Sony Group Corporation announced today that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, ...

Full story available on Benzinga.com

Why Is IBM Stock Declining On Thursday?

Kaustubh Bagalkote — Thu, 18 Jun 2026 13:29:22 +0000

International Business Machines Corp. (NYSE:IBM) shares fell during Thursday trading after sector peer Accenture plc (NYSE:ACN) lowered its fiscal guidance, triggering a broader selloff across the information technology services market.

Accenture Alters Fiscal 2026 Projections

Accenture altered its fiscal 2026 financial guidance before the market opened on Thursday.

The company narrowed its full-year sales guidance to a range of $71.763 billion to $72.460 billion, down from the previous range of $71.763 billion to $73.157 billion.

data-variant="card"
data-news-mode="manual"

Wall Street analysts maintain an annual revenue estimate of $74.006 billion.

Concurrently, Accenture raised its full-year adjusted EPS guidance to a range of $13.65 to $13.90, ...

Full story available on Benzinga.com

Kroger Stock Crashes 10% On Triple Whammy: Missed Earnings, Squeezed Margins And Soft Outlook

Lekha Gupta — Thu, 18 Jun 2026 13:00:50 +0000

The Kroger Co. (NYSE:KR) shares traded lower in Thursday’s premarket session after the grocery retailer reported mixed first-quarter results, with earnings narrowly missing Wall Street estimates despite stronger-than-expected revenue.

First-Quarter Results

Kroger reported adjusted earnings of $1.58 per share, missing the consensus estimate of $1.59. Revenue rose to $46.12 billion, topping analysts’ expectations of $45.47 billion.

Excluding fuel, identical sales increased 1.0% year over year. Sales excluding fuel and Vitacost increased 0.5% year over year.

Adjusted eCommerce sales climbed 19% from a year earlier. Profit from Kroger Precision Marketing increased by more than 20% year over ...

Full story available on Benzinga.com

Stock Market Today: S&P 500, Dow, Nasdaq 100 Futures Jump After Sharp Sell-Off On Fed Rates Pause— Freecast, Smith & Wesson In Focus (UPDATED)

Rishabh Mishra — Thu, 18 Jun 2026 12:47:15 +0000

(Editor’s note: The headline, ETFs and economic data were updated.)

U.S. stock futures rose on Thursday, as the Dow Jones, Nasdaq 100, and S&P 500 indices advanced, following Tuesday’s sharp sell-off.

Weekly initial jobless claims edged down by 4,000 to a seasonally adjusted 226,000 for the week ending June 13, keeping layoffs historically low.

Meanwhile, the Philadelphia Fed manufacturing index staged a major turnaround, jumping more than 10 points to a positive 10.3 reading in June to snap a month of flatlined regional factory growth.

On Wednesday, the Federal Reserve unanimously held the federal funds rate steady at 3.50%-3.75%, as widely expected, in the first policy meeting under new Fed Chair Kevin Warsh. He announced five task forces to review Fed communications, the balance sheet, data sources, productivity and jobs in the AI era, and the inflation framework itself.

Thursday will mark the last trading day of this week, as the markets will be closed for Juneteenth National Independence Day on Friday.

Meanwhile, the 10-year Treasury bond yielded 4.45%, and the two-year bond was at 4.17%. The CME Group's FedWatch tool‘s projections show markets pricing a 72.2% likelihood of the Federal Reserve leaving the current interest rates unchanged during July’s meeting.

Index	Performance (+/-)
Dow Jones	0.52%
S&P 500	0.86%
Nasdaq 100	1.47%
Russell 2000	1.05%

The SPDR S&P 500 ETF Trust (NYSE:SPY) and Invesco QQQ Trust ETF (NASDAQ:QQQ), which track the S&P 500 and Nasdaq 100, respectively, were higher in premarket on Thursday. The SPY was up 0.63% at $745.64, while the QQQ advanced by 1.61% to $734.13.

data-variant="card"
data-news-mode="manual"

Stocks In Focus

SpaceX

Space Exploration Technologies Corp. (NASDAQ:SPCX) rose 0.36% in premarket on Thursday after it closed lower for the first time since its listing on its fourth trading day, on Wednesday.

Smith & Wesson Brands

Smith & Wesson Brands Inc. (NASDAQ:SWBI) surged 15.37% after posting better-than-expected fourth-quarter results after Wednesday’s closing bell.

Benzinga’s Edge Stock Rankings indicate ...

Full story available on Benzinga.com

CarMax Analysts Boost Their Forecasts After Upbeat Q1 Results

Avi Kapoor — Thu, 18 Jun 2026 12:28:53 +0000

CarMax (NYSE:KMX) reported better-than-expected earnings for the first quarter on Wednesday.

The company posted quarterly earnings of $1.31 per share which beat the analyst consensus estimate of 94 cents per share. The company reported quarterly sales of $8.014 billion which beat the analyst consensus estimate of $7.410 billion.

The company introduced a new growth strategy centered on four pillars: improving offerings, enhancing customer experience, maximizing transaction value, and running lean operations. CarMax said the company remains on track to deliver $200 million in SG&A savings this fiscal year.

“I came to CarMax because I saw a strong foundation, an award-winning, people-first culture, and significant potential to ...

Full story available on Benzinga.com

Glucose Health, Inc. (GLUC) Reports Surge in GlucoDown Sales Among two of the Largest Retailers in the National Drug Store Channel

Globe Newswire — Thu, 18 Jun 2026 12:22:00 +0000

Bentonville, ARKANSAS, June 18, 2026 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTCID:GLUC), the maker of GlucoDown®, a scientifically formulated blood sugar support beverage, today announced continued growth and increasing momentum within the national pharmacy channel as demand from two of the largest U.S. pharmacy chains strengthened during the second quarter of 2026.

The Company recently reported a major expansion in retail distribution, with one national pharmacy chain nearly doubling the number of stores carrying GlucoDown® from approximately 1,250 locations to roughly 2,500 locations nationwide. In response to the broader retail footprint, Glucose Health increased its consumer advertising investment during April and May, specifically directing consumers to participating pharmacy locations where GlucoDown® is available.

Glucose Health continues to experience strong year-over-year momentum within the national pharmacy channel, as evidenced by recent sales data. During the first 24 weeks of 2026, the Company shipped more than 120% of the total GlucoDown® volume delivered to a major national pharmacy retailer during all of 2025. Another national drug store chain in the retail pharmacy space has recorded a sales increase of 135.7% for the most recent period from January 1, 2026, through June 6, 2026 versus the same period in 2025. Comparing numbers year-over-year, for the period from August 31, 2025, through June 6, 2026, revenues are up 193%.

Management believes the combination of expanded distribution and targeted consumer marketing is contributing to increased product demand and stronger replenishment orders from retail partners. The company believes that the increase of these two factors serves to underscore increasing demand and accelerating product adoption at retail.

"Our ...

Full story available on Benzinga.com

Top Wall Street Forecasters Revamp H.B. Fuller Expectations Ahead Of Q2 Earnings

Avi Kapoor — Thu, 18 Jun 2026 12:20:08 +0000

H.B. Fuller Company (NYSE:FUL) will release earnings for its second quarter after the closing bell on Wednesday, June 24.

Analysts expect the Saint Paul, Minnesota-based company to report quarterly earnings of $1.38 per share, up from $1.18 per share in the year-ago period. The consensus estimate for H.B. Fuller's quarterly revenue is $923.62 million. It reported $898.1 million last year, according to Benzinga Pro.

On April 16, H.B. Fuller increased its quarterly dividend by 4.3%.

Shares of H.B. Fuller rose 1.7% to close at $64.77 on Wednesday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at ...

Full story available on Benzinga.com

How To Earn $500 A Month From Methode Electronics Stock Ahead Of Q4 Earnings

Avi Kapoor — Thu, 18 Jun 2026 12:06:30 +0000

Ahead of Methode Electronics, Inc. (NYSE:MEI) fourth-quarter report on Wednesday, June 24, some investors may be eyeing potential gains from the company's dividends.

Currently, its annual dividend yield is 1.73%, with a quarterly dividend of 5 cents per share (20 cents per year).

To figure out how to earn $500 monthly from Methode Electronics, start with the yearly target of $6,000 ($500 x 12 months).

Next, divide this amount by Methode Electronics' $0.20 dividend: $6,000 / $0.20 = 30,000 shares.

So, an investor would need to own approximately $347,100 worth of Methode Electronics, or 30,000 shares to generate a monthly dividend income of $500.

Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $0.20 = 6,000 shares, or $69,420 to generate a monthly dividend income of $100.

Note that the dividend ...

Full story available on Benzinga.com

Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update

Globe Newswire — Thu, 18 Jun 2026 12:00:00 +0000

Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission

Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences

Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA
Resubmission for GTx-104 for the Treatment of Patients with aSAH

PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the fiscal year ended March 31, 2026.

"Since receipt of the U.S. Food and Drug Administration's (FDA) Complete Response Letter (CRL) in April 2026, we have been working diligently on addressing the cited items, and we look forward to a constructive discussion with the FDA as we continue to prepare our resubmission," said Prashant Kohli, CEO of Grace Therapeutics. "FDA approval of our New Drug Application (NDA) for GTx-104 for the treatment of aSAH would represent the first meaningful innovation in the standard of care for these patients in more than 40 years. As evidenced by the response among researchers, practitioners and industry leaders to the presentation of our Phase 3 STRIVE-ON trial results at major medical conferences throughout the fiscal year, we believe there is a significant desire in the marketplace for an intravenously administered nimodipine. We are confident in the robust data package supporting our NDA, and that the issues identified by the FDA can be successfully addressed in our resubmission."

Fiscal 2026 and Recent Corporate Highlights

On April 23, 2026, the FDA issued a CRL for the Company's NDA for GTx-104 for the treatment of patients with aSAH. In the CRL, the FDA referenced certain items in the Chemistry, Manufacturing, and Controls (CMC) and Non-Clinical sections of the application, which Grace believes it can address in a resubmission of its NDA. The cited items are related to additional leachable data time points for commercial product, non-clinical product toxicology risk assessments, and current Good Manufacturing Practices (cGMP) deficiencies with our contract manufacturing organization. No clinical deficiencies were identified. A Type A meeting with the FDA has been scheduled to potentially clarify the path forward and determine the appropriate next steps. The Company expects to provide a regulatory update after the receipt of official meeting minutes.
- Phase 3 STRIVE-ON trial results were presented at multiple major medical conferences over the last twelve months:
  - 2026 American Academy of Neurology, (April 18-22, 2026, Chicago, IL)
  - Society of Critical Care Medicine's Critical Care Congress (March 22-24, 2026, Chicago, IL)
  - American Association of Neuroscience Nurses (March 21-24, 2026, Dallas, TX)
  - Society of Vascular and Interventional Neurology (November 19-22, 2025, Orlando, FL)
  - 2025 Neurocritical Care Society (September 18-21, 2025, Montreal, Quebec)
- The U.S. Patent and Trademark Office issued a U.S. Patent No. 12,414,943, titled "Nimodipine Parenteral Administration". The method of use patent, published on September 16, 2025, covers the dosing regimen for IV administration of nimodipine used in the Phase 3 STRIVE-ON safety trial for GTx-104. Grace Therapeutics has established a multi-layered intellectual property estate for GTx-104, including five patents on the composition of the Company's formulation of nimodipine, which provide patent protection to 2037. The new patent on the IV dosing regimen for GTx-104 strengthens the Company's intellectual property position and extends protection to 2043. GTx-104 has also been granted Orphan Drug Designation from the FDA, which provides seven years of marketing exclusivity in United States if certain conditions are met upon FDA approval of the NDA.

Fiscal Year 2026 Financial Results

The Company reported a net loss of $7.8 million, or $0.47 loss per share for the fiscal year ended March 31, 2026, representing a $1.8 million decrease in net loss from $9.6 million, or $0.79 loss per share, for the fiscal year ended March 31, 2025.

Total research and development expenses were $2.4 million for the fiscal year ended March 31, 2026, compared with $9.5 million, for the fiscal year ended March 31, 2025. The decrease of $7.1 million was primarily due to the decrease in research activities of $7.5 million driven by the close-out of the GTx-104 pivotal Phase 3 safety clinical trial during the first calendar quarter of 2026, offset by a $0.4 million increase in external consulting and data management costs incurred in support of the NDA of GTx-104, which was submitted to the FDA in June 2025.

General and administrative expenses were $8.7 million for the fiscal year ended March 31, 2026, compared to $7.2 million for the fiscal year ended March 31, 2025. The increase of $1.5 million was primarily driven by $0.8 million in non-recurring legal and due diligence costs incurred in connection with strategic initiatives evaluated during the period, as well as increased professional fees and other general and administrative costs of $0.9 million primarily related to pre-commercial planning for GTx-104, offset in part by a decrease in salaries and benefits of $0.2 million primarily a result of decreased headcount.

Cash Runway

At March 31, 2026, the Company had cash and cash equivalents of $17.0 million, a net decrease of $5.1 million compared to cash and cash equivalents of $22.1 million at March 31, 2025. The Company plans to use its current cash towards resolving the items cited in the FDA's Complete Response Letter, working capital and other general corporate purposes. The Company believes its existing cash and cash equivalents will be sufficient to sustain planned operations through at least 12 months from the date of this press release.

About the STRIVE-ON Trial

The STRIVE-ON trial (NCT05995405) was a prospective, randomized open-label trial of GTx-104 compared with nimodipine oral capsules (oral nimodipine) in patients hospitalized with aSAH. 50 patients were administered GTx-104 and 52 patients received oral nimodipine. The primary endpoint was the number of patients with at least one episode of clinically significant hypotension reasonably considered to be caused by the drug, and additional secondary endpoints included safety, clinical, and pharmacoeconomic outcomes. The trial met its primary endpoint, with patients receiving GTx-104 observed to have a 19% reduction in at least one incidence of clinically significant hypotension compared to oral nimodipine (28% versus 35%). Other measures also favored GTx-104 or were comparable between the GTx-104 arm and the oral nimodipine arm, including: 54% patients on GTx-104 had relative dose intensity (RDI) of 95% or higher compared to only 8% on oral nimodipine, and 29% more patients on GTx-104 than on oral nimodipine had favorable functional outcomes at 90 days. In addition, there were fewer intensive care unit (ICU) readmissions, ICU days, and ventilator days for patients receiving GTx-104 versus oral nimodipine. Adverse events were comparable between the two arms and no new safety issues were identified with patients receiving GTx-104. All deaths in both arms of the trial were due to severity of the patient's underlying disease. There were eight deaths in the GTx-104 arm compared to four deaths in the oral nimodipine arm. The survival status of one patient in the oral nimodipine arm was unknown. No deaths were determined to be related to GTx-104 or oral nimodipine.

About aneurysmal Subarachnoid Hemorrhage (aSAH)

aSAH is bleeding over the surface of the brain in the subarachnoid space between the brain and the skull, which contains blood vessels that supply the brain. A primary cause of such bleeding is the rupture of an aneurysm in the brain. The result is aSAH, a relatively uncommon type of stroke that accounts for about 5% of all strokes and an estimated 42,500 U.S. hospital treated patients.

About GTx-104

GTx-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for IV infusion in aSAH patients to address significant unmet medical needs. The unique nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. GTx-104 provides a convenient IV delivery of nimodipine in the Intensive Care Unit potentially eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Intravenous delivery of GTx-104 also has the potential to lower food effects, drug-to-drug interactions, and eliminate potential dosing errors. Further, GTx-104 has the potential to better manage hypotension in aSAH patients. GTx-104 has been administered in over 200 patients and healthy volunteers and was well tolerated with significantly lower inter- and intra-subject pharmacokinetic variability compared to nimodipine oral capsules.

About Grace Therapeutics

Grace Therapeutics, Inc. (Grace Therapeutics or the Company) is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Grace Therapeutics' novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. Grace Therapeutics' lead clinical asset, GTx-104, is an IV infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. GTx-104 has been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States if certain conditions are met at NDA approval, and additional intellectual property protection with 52 granted and pending patents.

For more information, please visit: www.gracetx.com.

Forward-Looking Statements

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and "forward-looking information" within the meaning of Canadian securities laws (collectively, "forward-looking statements"). Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Grace Therapeutics to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements containing the terms "believes," "belief," "expects," "intends," "anticipates," "estimates," "potential," "should," "may," "will," "plans," "continue," "targeted" or other similar expressions to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The forward-looking statements in this press release, including statements regarding the Company's cash runway and cash position; the future prospects of the Company's GTx-104 drug candidate; the Company's belief that there is a significant desire in the marketplace for an alternative to orally administered nimodipine; the Company's belief that the issues identified by the FDA in the CRL can be successfully addressed in the Company's resubmission of an NDA for GTx-104; the expected timing and outcome of the Type A meeting with the FDA; the Company's expectations that the Type A meeting with the FDA will clarify the path forward and determine next steps; the Company's plans to provide a regulatory update after the receipt of official meeting minutes from such Type A meeting; GTx-104's potential to bring enhanced treatment options to patients suffering from aSAH; the ability of GTx-104 to potentially eliminate the need for nasogastric tube administration in unconscious or dysphagic patients; the potential of GTx-104 to lower food effects, drug-to-drug interactions, and to eliminate potential dosing errors; the potential of GTx-104 to better manage hypotension in aSAH patients; and the Company's intellectual property estate for GTx-104, are based upon Grace Therapeutics' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results ...

Full story available on Benzinga.com

Earnings Scheduled For June 18, 2026

Benzinga Insights — Thu, 18 Jun 2026 11:11:13 +0000

Companies Reporting Before The Bell

• Kroger (NYSE:KR) is expected to report quarterly earnings at $1.59 per share on revenue of $45.39 billion.

• Accenture (NYSE:ACN) is estimated to report quarterly earnings at $3.71 per share on revenue of ...

Full story available on Benzinga.com